Lilly's phase 3 miss dents Verzenio prospects in hot lung cancer field
admin 10th October 2017 Uncategorised 0Eli Lilly’s Verzenio needs to stand out in a new class of cancer meds, and the company was hoping success in lung cancer patients with a particular mutation could be just the ticket. But its ambitions in that department have now taken a hit.
More: Lilly's phase 3 miss dents Verzenio prospects in hot lung cancer field
Source: fierce